Top Markets
#1 Black Phoenix Black Phoenix +827.77%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +27.70%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#4 Bless Bless +22.57%
#5 pipedog pipedog +22.16%
#6 SAFEcoin SAFEcoin +20.09%
#7 Beam Beam +19.57%
#8 Magma Finance Magma Finance +19.26%
#9 PondCoin PondCoin +18.66%
#10 YFSX YFSX +15.99%
Coin of the day
Black Phoenix Black Phoenix
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Zymeworks Inc. Zymeworks Inc.

Zymeworks Inc.

ZYME
Classificação em ações #6233
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase,... Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Preço da ação
$29.29
Valor de mercado
$2.15B
Variação (1 dia)
-0.07%
Variação (1 ano)
96.15%
País
US
Negociar Zymeworks Inc. (ZYME)

Categoria

Healthcare
EPS de Zymeworks Inc. (ZYME)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Zymeworks Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Zymeworks Inc. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH